<em>BRAF V</em>600<em>E</em>mutation and expression of its protein in papillary thyroid carcinoma

董丽儒; 杨　虎; 李　双

doi:10.19401/j.cnki.1007-3639.2017.04.002

您当前的位置：

首页 >

文章列表页 >

BRAF V600Emutation and expression of its protein in papillary thyroid carcinoma

更新时间：2025-12-31

- BRAF V600Emutation and expression of its protein in papillary thyroid carcinoma
- China Oncology Vol. 27, Issue 4, Pages: 251-255(2017)
- 作者机构：
  
  1. 华北理工大学附属医院病理科,河北,唐山,063000
  2. 河北省武警总医院病理科,河北,石家庄,050081
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2017.04.002
  CLC：
- Published Online：05 May 2017，
  
  Published：05 May 2017
- 稿件说明：
移动端阅览
董丽儒,杨　虎,李　双,等. 甲状腺乳头状癌

董丽儒, 杨　虎, 李　双. BRAF V600Emutation and expression of its protein in papillary thyroid carcinoma[J]. China Oncology, 2017, 27(4): 251-255.
董丽儒,杨　虎,李　双,等. 甲状腺乳头状癌 DOI： 10.19401/j.cnki.1007-3639.2017.04.002.

董丽儒, 杨　虎, 李　双. BRAF V600Emutation and expression of its protein in papillary thyroid carcinoma[J]. China Oncology, 2017, 27(4): 251-255. DOI： 10.19401/j.cnki.1007-3639.2017.04.002.

摘要

背景与目的：BRAF V600E基因突变可作为甲状腺乳头状癌靶向治疗的靶点，因此检测患者BRAF基因状态对于能否应用靶向药物治疗具有重要意义。观察BRAF V600E基因突变及突变蛋白VE1在甲状腺乳头状癌中的表达情况，并分析其与甲状腺乳头状癌的临床病理特征及其预后的关系。方法：采用DNA测序法及免疫组织化学法分别检测108例甲状腺乳头状癌、54例甲状腺腺瘤和54例结节性甲状腺肿标本中BRAF基因突变及其相关蛋白VE1的表达。结果：108例甲状腺乳头状癌基因突变率为67.6%，VE1表达率为64.8%，与甲状腺良性病变相比差异有统计学意义(P0.05)，与临床病理参数间无相关性。结论：甲状腺乳头状癌BRAF V600E基因突变率和BRAF V600E蛋白表达水平增高，可以作为鉴别甲状腺良、恶性肿瘤的有效指标。免疫组织化学法检测甲状腺乳头状癌BRAF V600E蛋白的表达与其基因突变的一致性高，可间接有效地反映BRAF V600E基因突变的状态。BRAF V600E基因突变及突变蛋白的表达与甲状腺乳头状癌患者预后无关。

Abstract

Background and purpose: The BRAF V600E mutation is a highly attractive drug target. Therefore

determining the BRAF gene mutation status of patients is essential in order to assess patients’ eligibility for targeted BRAF gene inhibitor therapy. The aim of this study was to validate the utility of immunohistochemistry to rapidly obtain the BRAF gene mutation status. This study aimed to analyze the correlation of the BRAF V600E gene mutation and VE1 protein expression with the clinical pathological characteristics in papillary thyroid carcinoma (PTC). Methods: The mutation status of BRAF V600E was detected by DNA sequencing. Immunohistochemistry was used to detect the expression of BRAF V600E protein in 108 cases of PTC

54 cases of thyroid adenoma and 54 cases of normal thyroid tissue. Results: The gene mutation rate of BRAF V600E is 67.6%

and VE1 protein expression rate is 64.8% in 108 cases of PTC. The differences were statistically significant compared with thyroid adenoma and goiter (P0.05)

but have no correlation with the clinical pathological characteristics. Conclusion: BRAF V600E gene mutation and VE1 protein expression are useful biomarkers for the pathological diagnosis of PTC. High consistency was observed between the immunohistochemical staining results and the DNA sequencing results of BRAF V600E gene mutations. Immunohistochemical technique detecting the BRAF V600E protein expression can effectively reflect indirectly BRAF V600E gene mutation status in PTC. BRAF V600E gene mutation has no contribution to the development of papillary thyroid carcinoma.

关键词

Keywords

references

Views

4080

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical significance of BRAF V600E detection in fine-needle aspiration samples of thyroid nodule

Diagnostic value of dual-energy CT imaging for cervical lymph nodes metastasis in the patients with papillary thyroid cancer

The impact of American Cancer Joint Committee Revised Thyroid Cancer Staging System (8th edition)on staging of papillary thyroid carcinoma

The impact of thyroglobulin antibody on efficacy of 131I ablation in patients with papillary thyroid carcinoma

The relationship between the number of dissected central lymph nodes and clinical outcome in pN_1apapillary thyroid carcinoma

Related Author

朱晓丽

张　玲

周晓燕

陈　颖

张　皓

高丽丽

王　宇

稽庆海

Related Institution

复旦大学附属肿瘤医院病理科，复旦大学上海医学院肿瘤学系

复旦大学附属肿瘤医院头颈外科，复旦大学上海医学院肿瘤学系

福建医科大学省立临床学院，福建省立医院放射科

西门子医疗系统有限公司

山西省忻州市人民医院普通外科

AI问答

⁰

BRAF V600Emutation and expression of its protein in papillary thyroid carcinoma

DOI：10.19401/j.cnki.1007-3639.2017.04.002

摘要

Abstract

关键词

Keywords

references